Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the
“Company”), a medical technology company delivering intelligent,
rapid, non-invasive testing solutions, today announced the
successful debut of its Intelligent Fingerprinting Drug Screening
System at the 2023 Workplace Health & Safety Show in Sydney,
Australia on September 20th and 21st. The non-invasive, portable
system is designed to enable workplace health and safety managers
to conduct simple, non-invasive workplace drug testing anytime and
almost anywhere, serving as a deterrent against drug abuse and
encouraging employees to adhere to health and safety policies.
The Workplace Health & Safety Show is
Australia’s only workplace health and safety event, with thousands
of health and safety decision makers from multiple sectors
attending the live, interactive learning experience showcasing
cutting-edge technology, ideas, and practices in workplace safety.
Intelligent Bio Solutions stood alongside other industry leaders
collectively working toward healthy and safe work environments that
prioritize the well-being of all individuals.
Statistics from the Workplace Health &
Safety Show held in 2022 revealed that 96% of visitors surveyed
said it was important or very important to attend the exhibition to
find new products and services. Additionally, 92% had a level of
influence in health and safety purchases within their business,
with 60% having a high degree of influence or the final say. The
show is attended by organizations across a wide range of industries
and sectors, including construction, manufacturing, transportation
and logistics, education, local government, health and medical,
defense, agriculture, engineering, and infrastructure.
Peter Passaris, Vice President of Sales and
Operations at Intelligent Bio Solutions, said, “We have received an
incredible response from key decision makers and professionals
across a wide range of industries who have shown a keen interest in
our innovative drug screening system and are actively seeking more
information. This year’s show was focused on ‘shaping a safer
tomorrow’. Through our conversations, it was evident that the
commitment to workplace safety is growing stronger, and the
mindset has shifted from for cause testing to a more preventative
approach by conducting regular workplace drug screening. There
was significant enthusiasm around our solution as it targets
impairment, thus evaluating fitness for duty on the day of
testing. Additionally, it was appreciated as a preferred
choice of testing method by female participants in highly regulated
work environments due to its non-invasive and
dignified nature.”
The Intelligent Fingerprinting Drug Screening
System is increasingly recognized as the world’s first
fingerprint-based drug testing system that analyzes fingerprint
sweat to screen for recent drug use, including cannabis, cocaine,
opiates, and methamphetamine, in under ten minutes. A laboratory
confirmation service is also available. The innovative product
provides a quick, easy, non-invasive and dignified alternative to
traditional point-of-care drug testing methods, such as urine and
saliva. The system has applications within many sectors, and
current customers include employers in safety-critical industries
such as construction, manufacturing and engineering, transport and
logistics firms, drug treatment organizations, and coroners.
An introductory video demonstrating the
Intelligent Fingerprinting Drug Screening System is available
here.
About Intelligent Bio Solutions
Inc.
Intelligent Bio Solutions Inc. (the "Company")
(Nasdaq: INBS) is a medical technology company delivering
intelligent, rapid, non-invasive testing solutions. The Company
believes that its Intelligent Fingerprinting Drug Screening System
will revolutionize portable testing through fingerprint sweat
analysis, which has the potential for broader applications in
additional fields. This hygienic, and cost-effective system is
designed to screen for recent use of drugs commonly found in the
workplace, including opioids, cocaine, methamphetamine, and
cannabis. With sample collection in seconds and results in under
ten minutes, this technology would be a valuable tool for employers
in safety-critical industries. Additionally, the Company's
biosensor platform has the potential to test for up to 130
indications, ranging from glucose to immunological conditions and
communicable diseases. The Company’s current customer segments
include construction, manufacturing and engineering, transport and
logistics firms, drug treatment organizations, and coroners.
For more information, visit:
http://www.ibs.inc/
Forward-Looking Statements:
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, Intelligent Bio
Solutions Inc.’s ability to develop and commercialize its
diagnostic tests, realize commercial benefit from its partnerships
and collaborations, and secure regulatory approvals, among others.
Although Intelligent Bio Solutions Inc. believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Intelligent Bio Solutions
Inc. has attempted to identify forward-looking statements by
terminology, including “believes,” ”estimates,” ”anticipates,”
”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,”
”could,” ”might,” ”will,” ”should,” ”approximately” or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, included in Intelligent Bio Solutions’ public
filings filed with the Securities and Exchange Commission. Any
forward-looking statements contained in this release speak only as
of its date. Intelligent Bio Solutions undertakes no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events.
Company Contact:Intelligent Bio
Solutions Inc.info@ibs.inc
Investor Contact:Valter Pinto,
Managing DirectorKCSA Strategic CommunicationsPH: (212)
896-1254INBS@kcsa.com
Media Contact:Cheryl BillsonComma
Communicationscheryl.billson@commacomms.com
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/f02e69d9-e8d2-4068-969a-53ac6bc2a059
https://www.globenewswire.com/NewsRoom/AttachmentNg/3eee4a67-1ac8-4b86-86fb-1d77799e4f45
Intelligent Bio Solutions (NASDAQ:INBS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Intelligent Bio Solutions (NASDAQ:INBS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024